Targeted imaging and therapy of brain cancer using theranostic nanoparticles.
The past decade has seen momentous development in brain cancer research in terms of novel imaging-assisted surgeries, molecularly targeted drug-based treatment regimens or adjuvant therapies and in our understanding of molecular footprints of initiation and progression of malignancy. However, mortality due to brain cancer has essentially remained unchanged in the last three decades. Thus, paradigm-changing diagnostic and therapeutic reagents are urgently needed. Nanotheranostic platforms are powerful tools for imaging and treatment of cancer. Multifunctionality of these nanovehicles offers a number of advantages over conventional agents. These include targeting to a diseased site thereby minimizing systemic toxicity, the ability to solubilize hydrophobic or labile drugs leading to improved pharmacokinetics and their potential to image, treat and predict therapeutic response. In this article, we will discuss the application of newer theranostic nanoparticles in targeted brain cancer imaging and treatment.
Center for Molecular Imaging, Departments of Radiation Oncology and, and Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States.
Mahaveer Swaroop
MS
Bhojani
Marcian
M
Van Dort
Alnawaz
A
Rehemtulla
Brian D
BD
Ross
D000818:Animals; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D003952:Diagnostic Imaging / Q000379:methods*; D006801:Humans; D053758:Nanoparticles / Q000009:adverse effects / Q000627:therapeutic use*